Latest by Barbara Jungwirth
Why not all opioid prescriptions are unwise; racial, gender, age, and risk group disparities in HIV care; prophylactic antibiotic use rises among MSM on PrEP; navigating ambiguous HIV test results among PrEP users.
Based on 96-week data from the DRIVE-FORWARD study, the U.S. Food and Drug Administration has approved two new antiretroviral medications ahead of schedule.
The effect of specific regimens on some birth-related events; obstacles to PrEP among U.S. women; improving mortality and treatment success for HIV-positive people who inject drugs; kidney disease and “old” tenofovir.
Anticholinergics and cognitive performance; gender, physical activity, and cognitive decline; how peer networks can boost HIV self-testing among MSM of color; what HIV care providers don’t know about the Affordable Care Act.
Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.
The Medicines Patent Pool, which negotiates licenses with the manufacturers of new drugs that allow other companies to produce generic versions for distribution in low- and middle-income countries, is looking to expand beyond HIV drugs to medications...
Alcohol use worsens HIV care outcomes; sex-based differences in cognitive performance seen; higher cardiovascular risk among trans women; glycemic status related to cognitive function.
While almost 60% of people living with HIV globally are on treatment, the numbers for new seroconversions averted and HIV-related deaths are no longer improving.
In a recent survey of people not living with HIV, many still believed that people living with HIV should not be allowed to work in hospitals, restaurants, or universities, among other occupations, and 68% said they would be uncomfortable dating someo...
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.